Eiropas Savienība - latviešu - EMA (European Medicines Agency)

almirall s.a - dimethyl fumarate - psoriāze - imūnsupresanti - slimība ir indicēta vidēji smagas vai smagas plaknes psoriāzes ārstēšanai pieaugušajiem, kuriem nepieciešama sistēmiska zāļu terapija.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethyl fumarate - multiplā skleroze - imūnsupresanti - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - dimetilfumarāts - zarnās šķīstošā kapsula, cietā - 120 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - dimetilfumarāts - zarnās šķīstošā kapsula, cietā - 240 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).